Mr. Mazella worked with internal stakeholders to establish, resource and manage a process to identify or create opportunities at the earliest possible stage (i.e., prior to issuance of an RFI or RFP) on a program by program level and then triage and capture Government opportunities after issuance of a solicitation or sole source notice, which resulted in significant incremental revenue and in protection of the company’s Government share in the scientific research, public health, homeland security and defense markets.
Mr. Mazella developed and worked with a client to implement business processes that would ensure consistent utilization of company negotiation objectives for commercial services contracts, so that Government statements of work in issued purchase orders, delivery orders or contracts, did not exceed standard scope and pricing of service offerings.
Mr. Mazella directed and led the negotiation of a client’s GSA contract renewal, including the development and implementation of a successful strategy to narrow the selected class of basis of award customers and revamp completely the company’s pricing/discount strategy so as to maximize revenue from the client’s commercial customers and significantly reduce compliance risk. Mr. Mazella also managed the company’s response to the GSA IG’s pre-award audit and obtained a successful outcome. Based upon the business process that were either already in place or developed at the time of the renewal, the client received the highest possible performance rating from GSA each year for more than five years until the contract expired.
We assisted a client’s in-house staff and their retained GSA consulting company in ascertaining and negotiating the narrowest possible basis of award customer class and establishing pricing/discount policies that would maximize value and revenue from the client’s commercial sales. The favorability of the terms that resulted from the negotiations exceeded the client’s expectations.
At a non-traditional government contractor in the life sciences, Mr. Mazella co-led the development and implementation of a legislative, regulatory, marketing and sales strategy for pursuit of the Biosecurity market across the legislative and executive branches of the U.S. Government, State and Local Governments, and internationally. He spearheaded the company’s participation (at times in conjunction with other life science companies at trade groups) in the legislative process leading up to enactment of the PAHPA and PREP Act as a component the larger strategy for capture of the biosecurity market, which ultimately benefited the company, the industry and the public during the H1N1 Influenza Pandemic.
We negotiated a teaming agreement and a commercial item subcontract with an upper tier subcontractor and ultimately the prime contractor to provide real time PCR assays for use in the U.S. Postal Service’s Biohazard Detection System.
We negotiated with a small business prime contractor a teaming agreement and a commercial item subcontract to provide reagents and kit packaging/distribution for PCR assays to detect certain biothreat pathogens.
Mr. Mazella served as the architect of a strategy in obtaining and negotiating a “commercial services” contract (under FAR Subpart 12) valued at $24.5 million awarded by a U.S. military agency for research and development of a point of care benchtop medical device and assay panel for the identification of certain infectious disease pathogens.
At Celera Genomics, Mr. Mazella led the negotiation of a subscription license that authorized the National Institutes of Health to use Celera’s proprietary genomic and proteomic databases and software research tools for Government research and for the generation of U.S. Government intellectual property. Terms related to Government intellectual property rights were exceptionally complex and hinged on the contractual definition of a “gene” that was included in the agreement. News of this sale received world-wide attention in the life sciences and general press after the conclusion of the “race” to sequence the human genome.
As a GS-15 Senior Attorney at a bureau of the U.S. Treasury Department, Mr. Mazella advised his clients regarding the source selection process and negotiated major commercial information technology systems development contracts and licenses, six of which each exceeded $100 million in value, such as:
The Ca$h-Link cash concentration system, which concentrates funds and data (approximately $1 Trillion per year) of Government collections into the Federal Reserve Bank of New York for calculation of the daily cash balance for Government borrowing;
The Electronic Federal Tax Payment System for the secure electronic collection and deposit of virtually all business tax revenues (which at the time totaled approximately a trillion dollars per year) and accurate association of the value of the payment with the data; and
The Electronic Benefits Transfer (EBT) system, which was the first implementation of Smart Cards for the disbursement to beneficiaries of Government benefits, such as food stamps, at ATMs and POS devices. EBT systems for disbursement of government benefits are now implemented in many states.